JP2013542191A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013542191A5 JP2013542191A5 JP2013529669A JP2013529669A JP2013542191A5 JP 2013542191 A5 JP2013542191 A5 JP 2013542191A5 JP 2013529669 A JP2013529669 A JP 2013529669A JP 2013529669 A JP2013529669 A JP 2013529669A JP 2013542191 A5 JP2013542191 A5 JP 2013542191A5
- Authority
- JP
- Japan
- Prior art keywords
- combination
- seq
- thalidomide
- combination according
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38661910P | 2010-09-27 | 2010-09-27 | |
| US61/386,619 | 2010-09-27 | ||
| EP10180485 | 2010-09-27 | ||
| EP10180485.4 | 2010-09-27 | ||
| US201161437696P | 2011-01-31 | 2011-01-31 | |
| US61/437,696 | 2011-01-31 | ||
| US201161468607P | 2011-03-29 | 2011-03-29 | |
| US61/468,607 | 2011-03-29 | ||
| US201161486814P | 2011-05-17 | 2011-05-17 | |
| US61/486,814 | 2011-05-17 | ||
| PCT/EP2011/066648 WO2012041800A1 (en) | 2010-09-27 | 2011-09-26 | Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016206756A Division JP6231642B2 (ja) | 2010-09-27 | 2016-10-21 | 多発性骨髄腫およびｎｈｌ治療用の抗ｃｄ３８抗体およびレナリドミドまたはボルテゾミブ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013542191A JP2013542191A (ja) | 2013-11-21 |
| JP2013542191A5 true JP2013542191A5 (enExample) | 2014-11-13 |
| JP6087283B2 JP6087283B2 (ja) | 2017-03-01 |
Family
ID=43640677
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013529669A Expired - Fee Related JP6087283B2 (ja) | 2010-09-27 | 2011-09-26 | 多発性骨髄腫およびｎｈｌ治療用の抗ｃｄ３８抗体およびレナリドミドまたはボルテゾミブ |
| JP2016206756A Active JP6231642B2 (ja) | 2010-09-27 | 2016-10-21 | 多発性骨髄腫およびｎｈｌ治療用の抗ｃｄ３８抗体およびレナリドミドまたはボルテゾミブ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016206756A Active JP6231642B2 (ja) | 2010-09-27 | 2016-10-21 | 多発性骨髄腫およびｎｈｌ治療用の抗ｃｄ３８抗体およびレナリドミドまたはボルテゾミブ |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US8877899B2 (enExample) |
| EP (1) | EP2621531B8 (enExample) |
| JP (2) | JP6087283B2 (enExample) |
| KR (1) | KR101912957B1 (enExample) |
| CN (1) | CN103118706B (enExample) |
| AU (1) | AU2011310696B2 (enExample) |
| BR (1) | BR112013006769B1 (enExample) |
| CA (1) | CA2812631C (enExample) |
| DK (1) | DK2621531T3 (enExample) |
| ES (1) | ES2617446T3 (enExample) |
| HU (1) | HUE031956T2 (enExample) |
| IL (1) | IL224915A (enExample) |
| LT (1) | LT2621531T (enExample) |
| MX (1) | MX350540B (enExample) |
| NZ (1) | NZ607473A (enExample) |
| PL (1) | PL2621531T3 (enExample) |
| PT (1) | PT2621531T (enExample) |
| RU (1) | RU2595839C2 (enExample) |
| SG (1) | SG188345A1 (enExample) |
| SI (1) | SI2621531T1 (enExample) |
| WO (1) | WO2012041800A1 (enExample) |
| ZA (1) | ZA201301232B (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5362359B2 (ja) | 2005-10-12 | 2013-12-11 | モルフォシス アーゲー | ヒトＣＤ３８に特異的な完全ヒトＨｕＣＡＬＧＯＬＤ由来の治療抗体の生成とプロファイリング |
| EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| LT2621531T (lt) * | 2010-09-27 | 2017-04-10 | Morphosys Ag | Anti-cd38 antikūnas ir lenalidomidas arba bortezomibas, skirti išsėtinės mielomos ir nhl (nehodžino limfoma) gydymui |
| UA112170C2 (uk) * | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| CN104203982B (zh) | 2011-10-28 | 2018-08-31 | 特瓦制药澳大利亚私人有限公司 | 多肽构建体及其用途 |
| HUE036518T2 (hu) * | 2012-09-25 | 2018-07-30 | Morphosys Ag | Kombinációk és alkalmazásaik |
| DK2914302T3 (en) | 2012-11-05 | 2017-04-10 | Morphosys Ag | RADIOACTIVALLY MARKED ANTIBODY AND USES OF IT |
| UA118255C2 (uk) | 2012-12-07 | 2018-12-26 | Санофі | Композиція, яка містить антитіло до cd38 і леналідомід |
| US10342869B2 (en) * | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
| SG11201506956TA (en) | 2013-03-13 | 2015-10-29 | Sanofi Sa | Compositions comprising anti-cd38 antibodies and carfilzomib |
| ES2774976T3 (es) | 2013-04-29 | 2020-07-23 | Teva Pharmaceuticals Australia Pty Ltd | Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado |
| US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
| JP2017506640A (ja) * | 2014-02-14 | 2017-03-09 | セントローズ， エルエルシー | 細胞外標的化薬物共役体 |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| UA119352C2 (uk) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину |
| US10106620B2 (en) | 2014-06-16 | 2018-10-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Blocking CD38 using anti-CD38 F(ab′)2 to protect NK cells |
| MY192918A (en) * | 2014-09-09 | 2022-09-15 | Janssen Biotech Inc | Combination therapies with anti-cd38 antibodies |
| EA037749B1 (ru) | 2014-10-29 | 2021-05-18 | Тева Фармасьютикалз Острэйлиа Пти Лтд | ВАРИАНТЫ ИНТЕРФЕРОНА 2b |
| EP3227338A4 (en) | 2014-12-04 | 2018-05-16 | Janssen Biotech, Inc. | Anti-cd38 antibodies for treatment of acute myeloid leukemia |
| MA41555A (fr) * | 2015-02-17 | 2017-12-26 | Millennium Pharm Inc | Polythérapie pour le traitement du cancer |
| WO2016164656A1 (en) * | 2015-04-08 | 2016-10-13 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind cd38 |
| HRP20210552T1 (hr) * | 2015-05-13 | 2021-05-14 | Morphosys Ag | Liječenje multiplog mijeloma (mm) |
| CR20170526A (es) | 2015-05-20 | 2018-04-03 | Janssen Biotech Inc | ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38 |
| MY192978A (en) | 2015-06-22 | 2022-09-20 | Janssen Biotech Inc | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| HUE051896T2 (hu) | 2015-07-16 | 2021-03-29 | Inhibrx Inc | Multivalens és multispecifikus DR5-kötõ fúziós fehérjék |
| CN105079776B (zh) * | 2015-09-17 | 2018-09-21 | 中南大学 | 一种石蒜碱和硼替佐米组合物的药物用途 |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| PL3827845T3 (pl) | 2015-11-03 | 2022-07-11 | Janssen Biotech, Inc. | Formulacje podskórne przeciwciał anty-cd38 i ich zastosowania |
| AU2017226960B2 (en) * | 2016-03-04 | 2024-03-21 | Morphosys Ag | Clinical assessment of M-protein response in multiple myeloma |
| BR112019000544A2 (pt) | 2016-07-15 | 2019-04-24 | Takeda Pharmaceutical Company Limited | métodos e materiais para avaliar resposta a terapias de plasmoblasto- e depleção celular plasmática |
| US11124577B2 (en) | 2016-11-02 | 2021-09-21 | Engmab Sàrl | Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma |
| US20200121815A1 (en) | 2017-07-31 | 2020-04-23 | Actinium Pharmaceuticals, Inc. | Treatments for a hematological malignancy |
| WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
| CA3079242A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
| AU2019208102B2 (en) | 2018-01-12 | 2025-10-09 | Takeda Pharmaceutical Company Limited | Subcutaneous dosing of anti-CD38 antibodies |
| JP7541974B2 (ja) * | 2018-08-26 | 2024-08-29 | カーディフ・オンコロジー・インコーポレイテッド | Ｐｌｋ１標的のリン酸化状態及びｐｌｋ１阻害剤を用いた癌の治療 |
| WO2020187718A1 (en) * | 2019-03-15 | 2020-09-24 | Morphosys Ag | Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease |
| EP3980064A1 (en) | 2019-06-10 | 2022-04-13 | Takeda Pharmaceutical Company Limited | Combination therapies using cd-38 antibodies |
| WO2022112469A1 (en) | 2020-11-27 | 2022-06-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosis and monitoring of toxic epidermal necrolysis |
| WO2022232557A1 (en) * | 2021-04-30 | 2022-11-03 | Adagio Therapeutics, Inc. | Compounds specific to coronavirus s protein and uses thereof |
| US20240425567A1 (en) * | 2021-10-08 | 2024-12-26 | Invivyd, Inc. | Pharmaceutical formulations comprising anti-coronavirus s protein antibodies and uses thereof |
| TW202430548A (zh) * | 2022-09-29 | 2024-08-01 | 日商武田藥品工業股份有限公司 | Ｃｄ３８結合融合蛋白組合療法 |
| WO2025042742A1 (en) | 2023-08-18 | 2025-02-27 | Bristol-Myers Squibb Company | Compositions comprising antibodies that bind bcma and cd3 and methods of treatment |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| JP2003524587A (ja) | 1998-06-05 | 2003-08-19 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | 多発性骨髄腫を処置するための、ｃｄ３８に対する、遺伝子操作した抗体の使用 |
| US7223397B1 (en) | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
| BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| DE19933130A1 (de) | 1999-07-19 | 2001-01-25 | Giesecke & Devrient Gmbh | Operandenstapelspeicher und Verfahren zum Betreiben eines Operandenstapelspeichers |
| EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
| ES2338534T3 (es) | 2001-02-27 | 2010-05-10 | The Governement Of The Usa, Represented By The Secretary Department Of Health And Human Services | Analogos de talidomina como inhibidores de la angiogenesis. |
| CA2499816C (en) | 2002-09-27 | 2013-07-30 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| EP1587540B1 (en) | 2003-01-09 | 2021-09-15 | MacroGenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
| WO2005016326A2 (en) | 2003-07-11 | 2005-02-24 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Analogs of thalidomide as potential angiogenesis inhibitors |
| CA2555185C (en) | 2004-02-06 | 2020-03-24 | Morphosys Ag | Anti-cd38 human antibodies and uses therefor |
| JP2008504013A (ja) | 2004-02-06 | 2008-02-14 | モルフォシス・アクチェンゲゼルシャフト | 抗ｃｄ３８ヒト抗体及びその用途 |
| EA015584B1 (ru) * | 2005-03-23 | 2011-10-31 | Генмаб А/С | Антитело к cd38 человека и его применение |
| AR053489A1 (es) | 2005-05-24 | 2007-05-09 | Morphosys Ag | Generacion perfilado de anticuerpos terapeuticos totalmente derivados de hucal gold humanos especificos para cd38 humano |
| JP5362359B2 (ja) * | 2005-10-12 | 2013-12-11 | モルフォシス アーゲー | ヒトＣＤ３８に特異的な完全ヒトＨｕＣＡＬＧＯＬＤ由来の治療抗体の生成とプロファイリング |
| HRP20191115T1 (hr) * | 2006-09-26 | 2019-09-20 | Genmab A/S | Anti-cd38 u kombinaciji s kortikosteroidima zajedno s jednim ne-kortikosteroidnim kemoterapeutikom za liječenje tumora |
| ATE462248T1 (de) | 2006-09-28 | 2010-04-15 | Nokia Siemens Networks Gmbh | Steuerung der überlastdetektion in hsdpa systemen |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| NZ589880A (en) * | 2008-06-16 | 2012-10-26 | Immunogen Inc | Use of synergistic anti-cancer compositions comprising lenalidomide, at least one corticosteroid and at least one immunoconjugate |
| GB2461546B (en) | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
| EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
| EP2191842A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
| EP2191840A1 (en) * | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| EP2191843A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
| LT2621531T (lt) | 2010-09-27 | 2017-04-10 | Morphosys Ag | Anti-cd38 antikūnas ir lenalidomidas arba bortezomibas, skirti išsėtinės mielomos ir nhl (nehodžino limfoma) gydymui |
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
-
2011
- 2011-09-26 LT LTEP11761360.4T patent/LT2621531T/lt unknown
- 2011-09-26 ES ES11761360.4T patent/ES2617446T3/es active Active
- 2011-09-26 PT PT117613604T patent/PT2621531T/pt unknown
- 2011-09-26 BR BR112013006769-1A patent/BR112013006769B1/pt active IP Right Grant
- 2011-09-26 EP EP11761360.4A patent/EP2621531B8/en active Active
- 2011-09-26 US US13/825,325 patent/US8877899B2/en active Active
- 2011-09-26 PL PL11761360T patent/PL2621531T3/pl unknown
- 2011-09-26 MX MX2013003304A patent/MX350540B/es active IP Right Grant
- 2011-09-26 CN CN201180043775.1A patent/CN103118706B/zh active Active
- 2011-09-26 HU HUE11761360A patent/HUE031956T2/en unknown
- 2011-09-26 CA CA2812631A patent/CA2812631C/en active Active
- 2011-09-26 AU AU2011310696A patent/AU2011310696B2/en active Active
- 2011-09-26 RU RU2013113933/15A patent/RU2595839C2/ru active
- 2011-09-26 WO PCT/EP2011/066648 patent/WO2012041800A1/en not_active Ceased
- 2011-09-26 DK DK11761360.4T patent/DK2621531T3/en active
- 2011-09-26 KR KR1020137010537A patent/KR101912957B1/ko active Active
- 2011-09-26 NZ NZ607473A patent/NZ607473A/en unknown
- 2011-09-26 JP JP2013529669A patent/JP6087283B2/ja not_active Expired - Fee Related
- 2011-09-26 SI SI201131109A patent/SI2621531T1/sl unknown
- 2011-09-26 SG SG2013015235A patent/SG188345A1/en unknown
-
2013
- 2013-02-18 ZA ZA2013/01232A patent/ZA201301232B/en unknown
- 2013-02-26 IL IL224915A patent/IL224915A/en active IP Right Grant
-
2014
- 2014-09-29 US US14/500,366 patent/US9289490B2/en active Active
-
2016
- 2016-02-05 US US15/016,330 patent/US9765152B2/en active Active
- 2016-10-21 JP JP2016206756A patent/JP6231642B2/ja active Active
-
2017
- 2017-08-07 US US15/670,811 patent/US10308722B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013542191A5 (enExample) | ||
| RU2013113933A (ru) | Антитело к cd38 и леналтдомид или бортезомиб для лечения множественной миеломы и nhl | |
| JP2013542194A5 (enExample) | ||
| JP2017048208A5 (enExample) | ||
| JP2015514110A5 (enExample) | ||
| RU2015110981A (ru) | Комбинации и их применение | |
| RU2017137496A (ru) | Средство для лечения множественной миеломы (ММ) | |
| JP2016506388A5 (enExample) | ||
| NZ628943A (en) | Human antibodies to clostridium difficile toxins | |
| ME02798B (me) | Protutijela protiv dkk-1" | |
| IL273678B1 (en) | Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor | |
| JP2012523417A5 (enExample) | ||
| HRP20171992T1 (hr) | Protutijela protiv cgrp | |
| NZ574978A (en) | Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodies | |
| NZ705848A (en) | Anti-cd38 antibodies | |
| JP2017528462A5 (enExample) | ||
| JP2015530399A5 (enExample) | ||
| RU2018134595A (ru) | Композиции, включающие антитела к cd38 и карфилзомиб | |
| SI3042917T1 (en) | PROTITELES AGAINST N3PGL AMILOID BETA PEPTID AND THEIR APPLICATION | |
| FI3110440T3 (fi) | Anti-cd38-vasta-aineita akuutin lymfaattisen leukemian hoitamiseksi | |
| JP2017507954A5 (enExample) | ||
| NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| NZ631405A (en) | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer | |
| AR110719A1 (es) | Anticuerpos humanos a la toxina hemolisina a de s. aureus | |
| RU2016122340A (ru) | Il-17a-связующий агент и способы его применения |